
    
      After obtaining written informed consent, those patients who are deemed eligible for the
      study, will be randomized on Day 1, in a double-blinded manner, in a 3:1ratio to receive
      either oral STP1 (twice daily) or placebo (twice daily). The total study duration is 6 weeks,
      including a screening phase of up to 2 weeks, a treatment phase of 2 weeks and a
      post-treatment follow-up phase of 2 weeks.
    
  